Expert Interview
Discussing DARZALEX FASPRO® based regimen showing 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma
Ticker(s): JNJInstitution: Florida Oncology and Hematology
- Board-certified hematologist serving patients in Naples, Florida
- Manages 15 newly diagnosed multiple myeloma patients a month
- Familiar with DARZALEX FASPRO and studies
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
